Factors Differ for Early vs Late TNFi Switch in AS Patients

A study co-authored by John D. Reveille, MD, which found different outcomes in patients with ankylosing spondylitis (AS) who switched from their original tumor necrosis factor inhibitor (TNFi) treatment within two years versus after two years of treatment, was highlighted in an article by Biz News Post.

September 29, 2021